A subsequent study specifically evaluating FOXA2 reported an endometrioid adenocarcinoma mutation rate of 9.4%, with a spectrum of mutations again interpreted as consistent with a tumor suppressor role (22). This evidence concerns the gene FOXA2 and neoplasm.